Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

BACKGROUND: Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer (mCRC). Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:World J Gastrointest Oncol
Asıl Yazarlar: Ricci, Vincenzo, Granetto, Cristina, Falletta, Antonella, Paccagnella, Matteo, Abbona, Andrea, Fea, Elena, Fabozzi, Teresa, Lo Nigro, Cristiana, Merlano, Marco Carlo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Baishideng Publishing Group Inc 2020
Konular:
Retrospective Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7081116/
https://ncbi.nlm.nih.gov/pubmed/32206180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v12.i3.301
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller